Sep 28, 2018
NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1
Sep 05, 2018
NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th
Aug 07, 2018
NanoViricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study
Jul 23, 2018
NanoViricides, Inc. Welcomes Dr. Irach Taraporewala as the New CEO
Jul 12, 2018
NanoViricides Provides Update on Recent Events
Jun 26, 2018
Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
May 22, 2018
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
May 14, 2018
NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials
Apr 09, 2018
NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
Mar 19, 2018
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin
Feb 21, 2018
NanoViricides Files Quarterly Report for Period Ending December 31, 2017
Dec 06, 2017
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Nov 20, 2017
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
Nov 06, 2017
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
Oct 26, 2017
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
Oct 17, 2017
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
Sep 29, 2017
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
Sep 11, 2017
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017
Jul 10, 2017
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
Jun 26, 2017
NanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology